Home › SOLARA › Filing
🔔 Get instant alerts when SOLARA files quarterly results on BSE Start free trial →

Shareholders meeting

Filed: 17 Nov 2026, 20:15 IST Exchange: NSE Category: Management Change — Remuneration Revision
Postal Ballot Notice for approval of revised remuneration for two key executives - Mr. Mohanraj Sanjeevi, Whole Time Director: fixed salary increased from Rs. 85L to Rs. 95L per annum, plus Rs. 15L variable pay and eligibility for Rs. 40L LTIP over tenure till Dec 31, 2028 - Mr. Sandeep Shashikantha Rao, MD & CEO: fixed salary increased from Rs. 3.25Cr to Rs. 4Cr per annum, variable pay doubled from Rs. 75L to Rs. 1.5Cr, and Rs. 5Cr LTIP eligibility till Feb 20, 2028 - E-voting open Nov 18 to Dec 17, 2026; results by Dec 21, 2026 - Revisions effective July 1, 2026, for remainder of terms
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 SOLARA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add SOLARA to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Solara Active Pharma Sciences Limited

Important. The summary above is generated automatically from Solara Active Pharma Sciences Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.